N/A N=64 Validation of an Assay to Measure Cyclooxygenase-1 Activity
Healthy
Primary: A Reference Range in Normal Volunteers Taking a Routine Clinical Dose of Aspirin (81mg Daily) for 2 Weeks — 13 ng/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=21 EUS Guided Core Liver Biopsy and IGB Placement for the Diagnosis and Management of NASH and Obesity
Obesity · Non-Alcoholic Steatohepatitis
Primary: Weight Loss Achieved With Intragastric Balloon (IGB) — 17 Participants
Phase 4 N=5 Modulation of Monocyte Activation by Atorvastatin in HIV Infection
HIV Dementia
Primary: Change in Monocyte Surface Markers Expression (Expressed as Percentage), Following Treatment of Chronic HIV+/ HAART+ Subjects With Atorvastatin (T=12wks Versus T=0wk)…
Phase 3 N=719 An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL (c/mL) at Week 48 — 90; 93 Percentage of…
N/A N=535 Health-related Quality of Life in Patients on Anticoagulants
Atrial Fibrillation
Primary: Health Related Quality of Life (QoL) (HRQoL) Scores in the Spanish Adaptation of the Sawicki Questionnaire — 4.9; 3.6; 4.3; 3.6 Unit on scale
N/A N=30 Tele-Health Electronic Monitoring to Reduce Post Discharge Complications and Surgical Site Infections
Peripheral Vascular Disease
Primary: 30-Day Readmission (Any) — 4; 2 Participants
Phase 2 N=26 EXTEND Exercise Trial
Non-metastatic, Hormone naïve Prostate Cancer
Primary: Change in VO2peak in Usual Care Versus Exercise Training Arms — -3.23; -0.92 mL/kg/min
N/A N=66 A Proof of Concept Clinical Study to Investigate the Effects of an Experimental Cosmetic Moisturiser on the Barrier Function of Human Skin on the Face and Forearm
Skin Care
Primary: Change From Baseline in Transepidermal Water Loss (TEWL) Measurements on Day 29, Test Product Treated Versus (vs.) Untreated Sites on the Forearm — -0.59; 0.79 gram…
Phase 2 N=60 Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
HIV Infections
Primary: Percentage of Participants on the Ruxolitinib Arm Who Experienced Any Safety Milestone Events While On-Treatment — 2.5 percentage of participants
Phase 2 N=52 Pre-Exposure Prophylaxis (PrEP) Adherence Monitoring Using Dried Blood Spots
PrEP Adherence Monitoring
Primary: Steady State Concentrations of TFV-DP for Different Dosing Patterns of Truvada — 530; 997; 1605 fmol/punch
Phase 2 N=8 A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis
Psoriasis
Primary: Number of Participants With On-treatment Serious Adverse Events (SAEs) and Non-SAEs: Part A — 1; 0 Participants
Phase 3 N=295 Steroids In Eosinophil Negative Asthma
Asthma
Primary: Pairwise Comparison of Treatments Based on Composite Measure Using Treatment Failures, Asthma Control Days, and Percent Predicted FEV1. — 74; 35; 56; 12 Participants…
Phase 1 N=18 Study of Danirixin in Japanese Healthy Elderly Male Subjects
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Event (AE) and Serious Adverse Events in Part 1 — 1; 0; 0; 1 Participants
Phase 3 N=346 A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Treatment-resistant Depression
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated…
Phase 2 N=32 Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Myeloablative Conditioning · HLA-mismatched Bone Marrow Transplantation · Graft Survival
Primary: Cumulative Incidence of Non-relapse Mortality — 0 percent